Developing Tools to Probe DnaJB6 Dynamics in Spinobulbular Muscular Atrophy
开发工具来探测脊髓球性肌萎缩症中的 DnaJB6 动力学
基本信息
- 批准号:10515844
- 负责人:
- 金额:$ 11.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-15 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:ATP phosphohydrolaseAndrogen ReceptorAnimal ModelAwardBindingBiochemicalBiological AssayBiologyBiophysicsC10Cell modelCellsChemicalsComplexDisease ProgressionDrug TargetingElectron MicroscopyFutureGenetic DiseasesGoalsHomoHuntington DiseaseIn VitroLibrariesLigandsMapsMethodsModelingMolecularMolecular ChaperonesMolecular Sieve ChromatographyMuscular AtrophyMutateNeurodegenerative DisordersParkinson DiseasePathologicPeptidesPhasePhotometryProteinsRoleScanningSiteSolventsSpinobulbar Muscular AtrophySpinocerebellar AtaxiasStructureStructure-Activity RelationshipSurface Plasmon ResonanceSystemTechniquesTestingTimeToxic effectTrainingWorkbasedesigndisease phenotypeimprovedin vitro activityinnovationlight scatteringmolecular dynamicsmouse modelmutantneuromuscularnovelnovel strategiespolyglutaminepreventprotein aggregationprotein protein interactionproteostasisreceptorrecruitsmall moleculetool
项目摘要
PROJECT SUMMARY/ABSTRACT
Spinobulbar Muscular Atrophy (SBMA) is an incurable neurodegenerative disorder that is characterized
by the toxic accumulation of mutated androgen receptor (polyQ-AR) proteins. The molecular chaperone protein
DnaJB6 is specialized to prevent polyQ-AR aggregation in cells and suppress disease phenotypes by preventing
polyQ-AR aggregation and recruiting another chaperone protein, Hsp70 to polyQ-AR. While DnaJB6 represents
an exciting target for developing SBMA chemotherapeutics, its dynamic protein-protein interactions and complex
structure present significant challenges for efforts to discover and design DnaJB6 chemical ligands.
DnaJB6 associates with itself to form complexes that appear to exchange between larger and smaller
oligomeric states over time. I hypothesize that binding to either polyQ-AR or Hsp70 causes changes in the
stability of DnaJB6 complexes, and that these changes in DnaJB6 dynamics can be exploited to discover
chemical probes. DnaJB6 chemical probes could then be used to probe pathological aggregation in SBMA. To
test this hypothesis, I will characterize DnaJB6 complex stability and discover chemical matter that tunes DnaJB6
activity in the K99 phase of this award. In the R00 phase, I will use these molecules to probe SBMA in cell and
animal models. This work is significant because the tools resulting from my studies will not only have applicability
for studying SBMA, but also for other neurodegenerative disease where DnaJB6 can suppress protein
aggregation (i.e. Huntington's Disease, Spinocerebellar Ataxias, and Parkinson's Disease) and chaperone
biology more broadly. My proposed studies are innovative, as they will yield the first DnaJB6-targeted chemical
probes and a novel strategy to understand the molecular underpinnings of SBMA.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Oleta Tanitrea Johnson其他文献
Oleta Tanitrea Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
- 批准号:
DP230103210 - 财政年份:2023
- 资助金额:
$ 11.88万 - 项目类别:
Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
- 批准号:
10584689 - 财政年份:2023
- 资助金额:
$ 11.88万 - 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
- 批准号:
10650956 - 财政年份:2023
- 资助金额:
$ 11.88万 - 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
- 批准号:
10488954 - 财政年份:2023
- 资助金额:
$ 11.88万 - 项目类别:
Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
靶向肿瘤细胞巨噬细胞脂质相互作用以克服对雄激素受体靶向治疗的耐药性
- 批准号:
10651105 - 财政年份:2023
- 资助金额:
$ 11.88万 - 项目类别:
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease
ONCT-505(一种雄激素受体拮抗剂和降解剂)的临床前开发,作为肯尼迪病的新潜在治疗方法
- 批准号:
10603636 - 财政年份:2023
- 资助金额:
$ 11.88万 - 项目类别:
Proliferating cell nuclear antigen in regulation of androgen receptor signalings in castration-resistant prostate cancer cells
增殖细胞核抗原对去势抵抗性前列腺癌细胞雄激素受体信号传导的调节
- 批准号:
10544062 - 财政年份:2022
- 资助金额:
$ 11.88万 - 项目类别:
Effects of androgen receptor (AR) signaling on CD4+ T cell metabolism during airway inflammation
气道炎症期间雄激素受体 (AR) 信号对 CD4 T 细胞代谢的影响
- 批准号:
10534943 - 财政年份:2022
- 资助金额:
$ 11.88万 - 项目类别:
TITLE: BLADDER CANCER CHEMOPREVENTION USING THE ANDROGEN RECEPTOR INHIBITOR APALUTAMIDE
标题:使用雄激素受体抑制剂阿帕鲁胺进行膀胱癌化学预防
- 批准号:
10677989 - 财政年份:2022
- 资助金额:
$ 11.88万 - 项目类别:














{{item.name}}会员




